Cilostazole
Contraindicated
Textbook
Increased plasma levels and toxicity of cilostazole.
Should not be administered along with inhibitors of CYP3A4.
Source: KDT 7e · p555
Drug reference
Lopinavir
Antiretroviral
Also known as LPV
Antiretroviral
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
12 major
incl. contraindicated
PREGNANCY
Manufacturer advises use only if potential
FDA category + note
Top interactionssee all 12 →
- CilostazoleContraindicatedTextbookKDT 7e · p555
- ColchicineContraindicatedTextbookG&G 14e · p848, p854
- DisulfiramContraindicatedTextbookG&G 14e · p1245-1266
- IvabradineContraindicatedTextbookKDT 7e · p554
Mechanism
Lopinavir is a protease inhibitor.
Indications
HIV infection in combination with other antiretroviral drugsHIV-1 and HIV-2 infection in treatment-naïve or -experienced adults and children ≥14 daysHIV (available only in combination with ritonavir)
Dosing
- Adult
- low-dose ritonavir (r). They boost the concentrations of other antiretrovirals metabolised by CYP3A4, but have no antiretroviral activity themselves. ANTIVIRALS › HIV-FUSION INHIBITORS Enfuvirtide l DRUG ACTION 14-Jul-2018 Enfuvirtide inhibits the fusion of HIV to the host cell.…
Pharmacokinetics
Half-life
5–6
Bioavailability
—
Protein binding
98–99%
Metabolism
CYP3A4
Excretion
<3%
Side effects
Common
loose stoolsdiarrheanauseavomitingelevated total cholesterolelevated triglyceridesdiarrhoeaabdominal paindyslipidaemias
Pregnancy & lactation
Pregnancy
Manufacturer advises use only if potential
Drug interactions
Colchicine
Contraindicated
Textbook
Life-threatening toxicities of colchicine.
The drug is contraindicated in patients with hepatic or renal impairment requiring concomitant therapy with CYP3A4 inhibitors.
Source: G&G 14e · p848, p854
Disulfiram
Contraindicated
Textbook
Disulfiram-like reaction.
Should not be administered with disulfiram.
Source: G&G 14e · p1245-1266
Ivabradine
Contraindicated
Textbook
Increased plasma levels and toxicity of ivabradine, leading to excessive bradycardia and other adverse effects.
Concurrent use of drugs which inhibit CYP3A4 is contraindicated.
Source: KDT 7e · p554
Lomitapide
Contraindicated
Textbook
Increased risk of lomitapide adverse effects, particularly hepatotoxicity.
Lomitapide is contraindicated with inhibitors of CYP3A4.
Source: G&G 14e · p742
Metronidazole
Contraindicated
Textbook
Disulfiram-like reaction.
Should not be administered with metronidazole.
Source: G&G 14e · p1245-1266
Ranolazine
Contraindicated
Textbook
Increased plasma levels and toxicity of ranolazine, including QT prolongation.
Should not be given to patients taking CYP3A4 inhibitors.
Source: KDT 7e · p554
Tolvaptan
Contraindicated
Textbook
Increased levels and potential adverse effects of tolvaptan.
Tolvaptan should not be given to patients receiving inhibitors of CYP3A4.
Source: KDT 7e · p598
Atorvastatin
Severe
Textbook-cited
Increased risk of rhabdomyolysis and myopathy
Avoid concurrent use; if needed, use lowest statin dose
Source: KDT 7e · p948
Carbamazepine
Severe
Textbook-cited
Carbamazepine toxicity (diplopia, ataxia, drowsiness)
Avoid concurrent use or adjust dose with monitoring
Source: KDT 7e · p948
Cyclosporine
Severe
Textbook-cited
Nephrotoxicity and immunosuppression toxicity
Monitor cyclosporine levels and reduce dose
Source: KDT 7e · p948
Glibenclamide
Severe
Textbook-cited
Hypoglycemia
Avoid concurrent use or adjust dose
Source: KDT 7e · p948
Related guidelines
Antiretroviral therapy for HIV
NACO · Infectious Diseases · 2018
Skin and soft tissue infections
IDSA · Infectious Diseases · 2010
Hepatitis B — chronic infection
EASL · Gastroenterology · 2025
Urinary tract infection
EAU · Urology · 2024
Childhood pneumonia and respiratory infection
MOHFW · Paediatrics · 2021
Other Antiretroviral drugs
Ask House about Lopinavir
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, BNF·Verified: 2026-05-13 · House clinical team